bioAffinity's CyPath Lung to be Featured at Cleveland Clinic Symposium

summarizeSummary

bioAffinity Technologies announced its CyPath® Lung test will be featured at the Cleveland Clinic's "Advances in Early Lung Cancer Detection" symposium, enhancing product visibility and validation.

check_boxKey Events

• CyPath Lung Featured at Cleveland Clinic Symposium

  bioAffinity Technologies' CyPath® Lung test will be highlighted at the invitation-only "Advances in Early Lung Cancer Detection" symposium on April 16, 2026.

• CMO to Participate in Panel

  Dr. Gordon Downie, Chief Medical Officer, will join a panel discussing lung nodule management, emphasizing CyPath® Lung's benefits.

• Continued Industry Recognition

  This marks the seventh invitation for bioAffinity Technologies to present at this annual symposium, underscoring ongoing recognition within the medical community.

auto_awesomeAnalysis

This announcement provides positive visibility for bioAffinity Technologies' key diagnostic product, CyPath® Lung, at a prestigious, invitation-only symposium. For a company with a recent "going concern" warning, continued validation and market exposure for its core product are crucial for building investor confidence and demonstrating progress towards commercial viability. The participation of the Chief Medical Officer in a panel further highlights the company's expertise and the product's relevance in early lung cancer detection.